Key statistics
As of last trade Myriad Genetics Inc (MYD:FRA) traded at 14.60, 4.29% above its 52-week low of 14.00, set on Nov 20, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 14.60 |
---|---|
High | 14.60 |
Low | 14.60 |
Bid | 14.80 |
Offer | 15.10 |
Previous close | 14.30 |
Average volume | 227.57 |
---|---|
Shares outstanding | 91.04m |
Free float | 89.20m |
P/E (TTM) | -- |
Market cap | 1.41bn USD |
EPS (TTM) | -1.30 USD |
Data delayed at least 15 minutes, as of Nov 25 2024 07:16 GMT.
More ▼
Announcements
- Myriad Genetics Announces Incorporation of its Proprietary HRD platform in Illumina’s Updated Comprehensive Gene Panel Assay, TruSight™ Oncology 500 v2
- Myriad Genetics Announces Prequel® Prenatal Screening Can Now be Performed Eight Weeks into Pregnancy
- Myriad Genetics Expands Access to At-Home Early Fetal Sex DNA Test with Retail Launch
- Myriad Genetics Reports Third Quarter 2024 Financial Results; Updates 2024 Financial Guidance
- Myriad Genetics Comments on UnitedHealthcare’s Updated Medical Policy for Pharmacogenetic Testing
- Myriad Genetics to Release Third Quarter 2024 Financial Results on November 7, 2024
- Myriad Genetics and jscreen™ Announce Strategic Partnership to Advance Health Equity and Genetic Testing Access
- Myriad Genetics and Flatiron Health Partner to Make Genetic Testing More Accessible with Electronic Medical Record Integration
- Myriad Genetics Announces Five Research Collaborations to Study the Use of MRD Testing in Breast Cancer
- Myriad Genetics and Ultima Genomics to Explore the UG 100™ Sequencing Platform to Advance Clinical Test Offerings in Oncology and Reproductive Genomics
More ▼